NeuroBo Pharmaceuticals Enters Into Term Sheet With MThera Pharma To Out-license NB-01; Terms Not Disclosed
Portfolio Pulse from Benzinga Newsdesk
NeuroBo Pharmaceuticals has entered into a term sheet with MThera Pharma to out-license NB-01. The terms of the agreement have not been disclosed.
August 04, 2023 | 11:05 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
NeuroBo Pharmaceuticals has entered into a term sheet with MThera Pharma to out-license NB-01. The financial impact on NeuroBo is unclear as the terms of the agreement have not been disclosed.
The out-licensing of NB-01 to MThera Pharma could potentially bring in licensing fees or royalties to NeuroBo Pharmaceuticals, which could positively impact its financials. However, without the terms of the agreement being disclosed, it's difficult to assess the exact financial impact on NeuroBo. Hence, the score is neutral.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100